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###### Key points

Psychotropic drug use is very high in patients with young‐onset dementia in nursing homes.In almost half of the YOD patients, multiple psychotropic drugs are used.Apathy is strongly associated with less use of psychotropic drugs.

1. INTRODUCTION {#gps5116-sec-0008}
===============

Although dementia is typically regarded as a disease of old age, dementia also occurs at younger age. Young‐onset dementia (YOD) with first symptom onset before the age of 65[1](#gps5116-bib-0001){ref-type="ref"} is recognized as an important psychosocial and medical health problem with serious consequences for patients and their families.[2](#gps5116-bib-0002){ref-type="ref"}, [3](#gps5116-bib-0003){ref-type="ref"}, [4](#gps5116-bib-0004){ref-type="ref"}

The prevalence[4](#gps5116-bib-0004){ref-type="ref"}, [5](#gps5116-bib-0005){ref-type="ref"}, [6](#gps5116-bib-0006){ref-type="ref"} of YOD has been estimated between 67 and 98 per 100 000 for the age of 45 to 65 years and 12 per 100 000 for the age of 30 to 44 years. In The Netherlands, it is estimated that there are approximately 12 000 people with YOD of whom approximately 2500 are residing in nursing homes.[7](#gps5116-bib-0007){ref-type="ref"}

In patients with young onset as well as late‐onset dementia (LOD), Alzheimer\'s disease is the most common cause ranging from 30% to 34% in YOD. In patients with YOD, however, there are larger proportions of frontotemporal dementia (FTD), alcohol‐related dementia (AlcD), and other causes of cognitive deterioration[5](#gps5116-bib-0005){ref-type="ref"}, [8](#gps5116-bib-0008){ref-type="ref"} compared with those with LOD.

Dementia often comes with neuropsychiatric symptoms (NPSs), such as depression, agitation, or apathy. In YOD, research has already demonstrated that NPSs are frequent and burdensome[9](#gps5116-bib-0009){ref-type="ref"} and are important predictors for institutionalization.[10](#gps5116-bib-0010){ref-type="ref"} However, studies on frequency and type of NPS are scarce and show conflicting results. In community‐dwelling patients with young‐onset Alzheimer\'s disease (YO‐AD), these patients showed less NPS than a comparable group with LO[ad.]{.smallcaps} [9](#gps5116-bib-0009){ref-type="ref"}, [11](#gps5116-bib-0011){ref-type="ref"} However, in the total group of community‐dwelling patients, those with YOD had significantly greater levels of both hyperactive symptoms and apathy and significantly lower levels of mood symptoms.[10](#gps5116-bib-0010){ref-type="ref"} In institutionalized YOD patients, our study showed that significant NPS occurred in almost 90% of all patients, consisting most frequently of agitation (66%) and apathy (56%), where psychotic symptoms and depressive symptoms were less frequent (11% and 19%, respectively). The prevalence and severity of NPS were higher than in institutionalized LOD patients.[12](#gps5116-bib-0012){ref-type="ref"}

Neuropsychiatric symptoms may be treated with psychotropic drugs, which have limited efficacy and frequent, severe side effects. Especially, the use of antipsychotic drugs in patients with dementia has been shown to increase the risk of death,[13](#gps5116-bib-0013){ref-type="ref"}, [14](#gps5116-bib-0014){ref-type="ref"} stroke,[15](#gps5116-bib-0015){ref-type="ref"}, [16](#gps5116-bib-0016){ref-type="ref"} and cardiac arrhythmias[17](#gps5116-bib-0017){ref-type="ref"} although this is not confirmed in a more recent meta‐analysis including randomized controlled trials.[18](#gps5116-bib-0018){ref-type="ref"} A recent Norwegian study in nursing home patients did not show an association of PDU with long‐term mortality risk.[19](#gps5116-bib-0019){ref-type="ref"} Less controversial is the occurrence of adverse effects such as parkinsonism,[20](#gps5116-bib-0020){ref-type="ref"} gait disturbances, and daytime sedation,[21](#gps5116-bib-0021){ref-type="ref"} which have been shown to negatively influence quality of life.[22](#gps5116-bib-0022){ref-type="ref"}

All current medical guidelines on management of NPSs in dementia recommend psychosocial interventions as first‐line treatment of NPSs. Nonpharmacological approaches have been used successfully to reduce NPSs.[23](#gps5116-bib-0023){ref-type="ref"}, [24](#gps5116-bib-0024){ref-type="ref"} Despite these recent recommendations, psychotropic drugs are widely prescribed in dementia patients with NPSs. Studies regarding psychotropic drug use in nursing home patients with LOD found that 37% to 78% had at least one prescription of a psychotropic drug, 21% to 54% used antipsychotics, 15% to 31% sedatives, 9% to 38% anxiolytics, and 19% to 47% antidepressants.[25](#gps5116-bib-0025){ref-type="ref"}

An association between specific NPSs and the use of different types of psychotropic drugs has been shown.[26](#gps5116-bib-0026){ref-type="ref"} Antipsychotic medication was more frequently prescribed in patients with at least one NPS[27](#gps5116-bib-0027){ref-type="ref"}, [28](#gps5116-bib-0028){ref-type="ref"} and more specifically in patients with psychosis, agitation, and nighttime behavior.[29](#gps5116-bib-0029){ref-type="ref"}

Studies on PDU in YOD patients are scarce. Thus far, after a comprehensive search in PUBMED, only one study was found. In this study, in community‐dwelling YOD patients, PDU[30](#gps5116-bib-0030){ref-type="ref"} was as high as 52%. In a study with a comparable community‐dwelling LOD group, this was 28.8%, and increasing age and moderate to severe depressive symptoms were positively associated with the total use of psychotropic drugs.[31](#gps5116-bib-0031){ref-type="ref"} No studies were found on PDU in institutionalized YOD patients. In The Netherlands, the Dutch Knowledge Center for YOD, a cooperation of over 20 care organizations delivering specialized care for persons with YOD, provides a unique opportunity for research in residential care for YOD. The YOD special care units are usually part of (larger) nursing homes, delivering care for five to 25 YOD patients per unit, with a specially trained multidisciplinary nursing home staff and services for younger persons. In these nursing homes, integrated medical care is delivered by elderly care physicians,[32](#gps5116-bib-0032){ref-type="ref"} who are generally responsible for all drug prescriptions in the nursing home setting.

The aim of this study is (a) to gain insight into the point prevalence of psychotropic drug use in institutionalized patients with YOD and (b) to study the association between age, gender, dementia subtype, severity of dementia, NPSs, and the use of psychotropic drugs.

2. METHODS {#gps5116-sec-0009}
==========

2.1. Participants {#gps5116-sec-0010}
-----------------

This study is part of the Behavior and Evolution in Young‐Onset Dementia (BEYOnD) study.[33](#gps5116-bib-0033){ref-type="ref"} In this study, eight Dutch nursing homes with in total 21 specialized care units for YOD patients participated. Inclusion took place between 2005 and 2009. Patients were considered for inclusion provided that they (a) met the DSM‐IV‐TR criteria (American Psychiatric Association, 2000) for dementia (b) with documented dementia symptoms in their entire medical record before the age of 65 and (c) resided in a nursing home with specialized care for YOD and (d) the legal representative gave their informed consent on participation in the study. Only one representative declined the use of her husband\'s data for study purposes.

The study protocol is in accordance with the Declaration of Helsinki, with the Dutch legislation on medical research, and it is in agreement with the Conduct Health Research of the Dutch federation of Biomedical Scientific Societies. The study protocol was approved by the Regional Medical Ethics Review Committee Arnhem‐Nijmegen. The committee stated that, in accordance with Dutch legislation, the study can be performed without a review procedure by the committee because in the study, only observational data gathered by nursing staff as part of their daily work were collected.

2.2. Data collection {#gps5116-sec-0011}
--------------------

Baseline characteristics such as age, gender, marital status, and time of institutionalization were retrieved from patients\' charts.

The diagnosis and dementia subtype were retrieved from the medical record. The type of dementia was recorded as stated in the medical record, in the original diagnostic letter from the physician that established the diagnosis. Most patients had a comprehensive medical work‐up determining the type of dementia, including neurological and neuropsychological tests and imaging at a memory clinic. If this was not the case, then diagnosis was recorded as *not otherwise specified*.

The types of dementia were categorized into Alzheimer\'s dementia (AD), vascular dementia (VaD), FTD, AlcD, and "other causes" of dementia, including Lewy body dementia (LBD), Huntington\'s disease, dementia caused by acquired brain injury, and/or encephalopathy. On the day of inclusion, vocational nurses specifically assigned for individual patients were interviewed by the researcher (AM, elderly care physician) and a research assistant (psychologist) to collect the following assessments.

2.3. Assessments {#gps5116-sec-0012}
----------------

The actual prescription of psychotropic drugs on the day of assessment was retrieved from the medical chart, using the Anatomical Therapeutical Chemical Classification[34](#gps5116-bib-0034){ref-type="ref"} and grouped into antipsychotics (N05A), anxiolytics (N05B), hypnotics/sedatives (N05C), antidepressants (N06A), and anti‐epileptics. All psychotropic drug use was registered, regular as well as Pro Re Nata (PRN) prescriptions. A PRN prescription indicates the possible administration as needed but is not necessarily administered at the assessment day.

The following data were collected for correlates. NPSs were assessed using the Neuropsychiatric Inventory---Nursing Home (NPI‐NH) version, Dutch version.[35](#gps5116-bib-0035){ref-type="ref"} The NPI‐NH includes 12 NPSs: delusions, hallucinations, agitation, depression, anxiety, euphoria/elation, apathy/indifference, disinhibition, irritability, aberrant motor behavior, nighttime disturbances, and appetite/eating change. The frequency and severity of each symptom are rated on a four‐point (1‐4) and three‐point (1‐3) Likert scale, respectively.

Agitation was assessed in more detail using the Cohen‐Mansfield Agitation Inventory (CMAI), Dutch version.[36](#gps5116-bib-0036){ref-type="ref"}, [37](#gps5116-bib-0037){ref-type="ref"} The CMAI assesses 29 types of agitated behavior. The frequency of each symptom is rated on a seven‐point scale ranging from 1 (*never*) to 7 (*several times an hour*). The CMAI has a well‐established (test‐retest and interrater) reliability and validity[38](#gps5116-bib-0038){ref-type="ref"} in nursing home patients.

Severity of the dementia was assessed using the Global Deterioration Scale,[39](#gps5116-bib-0039){ref-type="ref"} which consists of a seven‐point scale ranging from 1 (*no cognitive decline*) to 7 (*very severe cognitive decline*). GDS scores of 4 to 6 denote moderate, moderately severe, and severe cognitive decline, respectively.

2.4. Analysis {#gps5116-sec-0013}
-------------

In the analysis of NPI‐NH scores, frequency and severity scores were multiplied, and each individual NPS was considered clinically relevant if the frequency × severity score was more than or equal to 4, for comparability with previous studies on NPS in dementia.[40](#gps5116-bib-0040){ref-type="ref"}, [41](#gps5116-bib-0041){ref-type="ref"} Six NPI‐NH items were grouped into the following categories: psychosis (hallucinations and delusions) and agitation (agitation, disinhibition, irritability, and aberrant motor behavior).[42](#gps5116-bib-0042){ref-type="ref"} For inclusion in either category, at least one separate symptom had to be clinically relevant. Depression, anxiety, apathy, nighttime behavior, eating changes, and euphoria were analyzed separately.

Clinically relevant agitation as measured with the CMAI was defined as behavior occurring at least once a week or more (frequency score ≥ 3). CMAI items were categorized into physically nonaggressive behavior, physically aggressive behavior, and verbal agitated behavior.[43](#gps5116-bib-0043){ref-type="ref"}

Binomial logistic regression was applied with regular psychotropic drug use (total drug use and use of individual drug types, excluding anti‐epileptics because the indication for the prescription could not be verified) as the dependent variable and age (in 5‐year groups), gender, severity of dementia, type of dementia, and NPSs as independent variables. Two separate models were analyzed: one model with NPI‐NH symptoms and the other model with CMAI symptoms as independent variables for NPS. We accepted *p* \< .05 as significant.

3. RESULTS {#gps5116-sec-0014}
==========

3.1. Patients\' characteristics {#gps5116-sec-0015}
-------------------------------

Two hundred thirty YOD patients met the inclusion criteria. Of five patients, data on NPS were incomplete, resulting in inclusion of 225 patients. Patients had a mean age of 60.1 years (SD 7.3); most of the patients had a GDS stage 6, and 53% were male (Table [1](#gps5116-tbl-0001){ref-type="table"}).

###### 

Patients\' characteristics

  ---------------------------------------------------------------------- ----------------------------
  Age mean, y                                                            60.1 (range 39‐78)
  \<44 years                                                             11 (5%)
  45--54                                                                 43 (19%)
  55--64                                                                 115 (51%)
  \>65                                                                   56 (25%)
  Gender (% male)                                                        n (%), 120 (53%)
  Dementia stage (GDS)                                                   
  GDS ≤4 (mild to moderate dementia)                                     39 (17%)
  GDS 5 (moderately severe dementia)                                     55 (24%)
  GDS 6 (severe dementia)                                                68 (30%)
  GDS 7 (very severe dementia)                                           63 (28%)
  Type of dementia                                                       
  Alzheimer\'s dementia                                                  72 (32%)
  Vascular dementia                                                      29 (13%)
  Frontotemporal dementia                                                36 (16%)
  Alcohol‐related dementia                                               40 (18%)
  Dementia NOS and other types of dementia                               48 (21%)
  Neuropsychiatric symptoms                                              
  NPI‐NH any significant symptom[a](#gps5116-note-0002){ref-type="fn"}   202 (89.8%; CI, 85.1‐93.1)
  Two or more significant symptoms                                       167 (74.2%; CI, 68.1‐79.5)
  NPI‐NH agitation cluster[b](#gps5116-note-0003){ref-type="fn"}         149(66.2%; CI, 59.8‐72.1)
  NPI‐NH psychosis cluster[c](#gps5116-note-0004){ref-type="fn"}         25 (11.1%; CI, 7.6‐15.9)
  CMAI any significant symptom[d](#gps5116-note-0005){ref-type="fn"}     197 (87.6%; CI, 82.6‐91.2)
  ---------------------------------------------------------------------- ----------------------------

Abbreviations: CI, confidence interval; CMAI, Cohen‐Mansfield Agitation Inventory; GDS, global deterioration scale; GRAD, Guidelines for the Rating of Awareness Deficits; NOS, not otherwise specified; NPI‐NH, Neuropsychiatric Inventory---Nursing Home.

Any item with frequency (F) × severity (S) score more than or equal to 4.

One or more significant symptom(s) of agitation/aggression, disinhibition, irritability, and/or aberrant motor behavior.

One or both significant symptoms of delusions and hallucinations.

Any item occurring once a week or more.

3.2. Prevalence of psychotropic drug use {#gps5116-sec-0016}
----------------------------------------

Over 80% of the patients used any regular prescribed psychotropic drug (Table [2](#gps5116-tbl-0002){ref-type="table"}). In addition, antidementia drugs were used by 18 patients (8.0%), and anti‐epileptic drugs were used by 26% of the patients; half of these patients had a diagnosis of epilepsy in their medical record.

###### 

Prevalence of psychotropic drug use among patients (n = 225)

  Type of Medication (ATC Code)                                                 Regular Prescription   Prescription of Medication PRN        
  ----------------------------------------------------------------------------- ---------------------- -------------------------------- ---- --------
  Any psychotropic drug                                                         183                    (81.3)                           60   (26.)
  Antipsychotic drugs (N05A)                                                    114                    (50.7)                           11   (4.9)
  Anxiolytic drugs (N05B)                                                       69                     (30.7)                           31   (13.8)
  Hypnotics (N05C)                                                              40                     (17.8)                           14   (6.2)
  Antidepressant drugs (N06A)                                                   111                    (49.3)                           0    \(0\)
  Single drug use                                                                                                                            
  Only antipsychotic                                                            25                     (11.1)                                
  Only anxiolytic                                                               9                      (4.0)                                 
  Only hypnotics                                                                6                      (2.7)                                 
  Only antidepressant                                                           37                     (16.4)                                
  Total single drug use                                                         77                     (34.2)                                
  Combination of two psychotropic drugs[a](#gps5116-note-0006){ref-type="fn"}                                                                
  Antipsychotic + anxiolytic                                                    17                     (6.7)                                 
  Antipsychotic + hypnotics                                                     5                      (2.2)                                 
  Antipsychotic + antidepressant                                                28                     (12.4)                                
  Anxiolytic + hypnotics                                                        7                      (3.1)                                 
  Anxiolytics + antidepressant                                                  8                      (3.6)                                 
  Antidepressant drugs + hypnotics                                              2                      (0.9)                                 
  Total use of two drugs                                                        67                     (29.8)                                
  Combination of three or more drugs[a](#gps5116-note-0006){ref-type="fn"}                                                                   
  Antipsychotic + anxiolytic + antidepressant                                   19                     (8.4)                                 
  Antipsychotic + antidepressant drugs + hypnotics                              11                     (4.8)                                 
  Antipsychotic + anxiolytic + hypnotics                                        3                      (1.3)                                 
  Antipsychotic + anxiolytic + antidepressant + hypnotics                       6                      (2.7)                                 
  Total use of three or more drugs                                              39                     (17.3)                                

Combinations of psychotropic drugs, except antidementia drugs, and anti‐epileptic drugs.

One third of the patients used one psychotropic drug; almost half of the patients used two or more, and 17% used three or more psychotropic drugs (antidementia drugs and anti‐epileptics were excluded in the combinations).

Antipsychotics, anxiolytics, and antidepressant drugs were the most frequently prescribed drugs. The most prevalent combinations of regularly prescribed drugs were an antipsychotic with an antidepressant or with an anxiolytic drug (Table [2](#gps5116-tbl-0002){ref-type="table"}).

3.3. Correlates of psychotropic drug use {#gps5116-sec-0017}
----------------------------------------

Results of the multivariate logistic regression analysis for correlates of PDU are represented in Tables [3](#gps5116-tbl-0003){ref-type="table"} and [4](#gps5116-tbl-0004){ref-type="table"}. Male gender was significantly associated with higher PDU (OR 2.27, *p* = .026, and [or 2.14,]{.smallcaps} *p* [= .035,]{.smallcaps} respectively, for the two models). No significant associations between age and PDU were found[.]{.smallcaps} Dementia subtype and dementia severity were also not significantly associated with total PDU. However, anxiolytic drugs were less frequently prescribed in patients with GDS stage less than or equal to 4 (or 0.12, *p* = .002, and/or 0.16, *p* = .007, respectively, for the two models), and antipsychotics were more frequently prescribed in non‐Alzheimer\'s type dementia (or 2.07, *p* = .045) in the NPI model.

###### 

Association between patient characteristics, NPS (NPI‐NH), and psychotropic drug use in Dutch nursing home patients with young‐onset dementia

                                                        Total Psychotropic Drugs                          Antipsychotic Drugs   Anxiolytic Drugs   Antidepressant Drugs                              Hypnotics                                                                                                                                                                                                                           
  ----------------------------------------------------- ------------------------------------------------- --------------------- ------------------ ------------------------------------------------- ----------- ---------- ------------------------------------------------- ---------- ---------- ------------------------------------------------- ---------- ---------- ------------------------------------------------- ---------- -----------
  Age                                                   1.00                                              0.95                  1.01               1.00                                              0.96        1.05       1.00                                              0.96       1.05       1.01                                              0.97       1.05       0.98                                              0.93       1.04
  Gender (male)                                         **2.27** [a](#gps5116-note-0008){ref-type="fn"}   **1.10**              **4.69**           1.460                                             0.83        2.56       0.88                                              0.48       1.27       1.50                                              0.86       2.61       0.53                                              0.24       1.14
  GDS 2‐5 (GDS 6‐7 reference)                           0.66                                              0.28                  1.55               1.16                                              0.60        2.25       **0.42** [a](#gps5116-note-0008){ref-type="fn"}   **0.20**   **0.87**   1.02                                              0.53       1.96       0.55                                              0.22       1.36
  Non‐Alzheimer\'s type (Alzheimer\'s type reference)   0.95                                              0.39                  2.32               **2.07** [a](#gps5116-note-0008){ref-type="fn"}   **1.02**    **4.20**   1.04                                              0.50       2.19       0.76                                              0.39       1.52       0.70                                              0.28       1.76
  NPI psychosis cluster                                 0.71                                              0.24                  2.18               1.89                                              0.75        4.77       1.53                                              0.60       3.86       0.64                                              0.27       1.54       1.12                                              0.35       3.56
  Agitation cluster                                     2.67                                              0.74                  9.65               2.03                                              0.60        6.95       1.30                                              0.52       3.29       0.94                                              0.41       2.18       1.08                                              0.39       3.02
  Depression                                            1.84                                              0.63                  5.41               1.90                                              0.68        5.33       1.11                                              0.50       2.46       **2.30** [a](#gps5116-note-0008){ref-type="fn"}   **1.10**   **4.83**   0.32                                              0.10       1.10
  Anxiety                                               0.75                                              0.25                  2.28               0.86                                              0.27        2.75       1.24                                              0.53       2.92       0.71                                              0.31       1.64       1.18                                              0.39       3.62
  Apathy                                                **0.27** [a](#gps5116-note-0008){ref-type="fn"}   **0.08**              **0.88**           0.72                                              0.35        1.49       0.62                                              0.29       1.33       0.78                                              0.38       1.59       **0.35** [a](#gps5116-note-0008){ref-type="fn"}   **0.14**   **0.90**
  Nighttime behavior                                    2.13                                              0.46                  9.87               2.47                                              0.97        6.31       **3.08** [a](#gps5116-note-0008){ref-type="fn"}   **1.25**   **7.61**   0.57                                              0.24       1.40       **6.71** [a](#gps5116-note-0008){ref-type="fn"}   **2.43**   **18.51**

Abbreviation: OR, odds ratio.

If value 1 is not included in the 95% confidence interval, the *p* value is significant (*p* \< .05); these results are printed in bold.

95% confidence interval (lower boundary, upper boundary).

###### 

Association between patient characteristics, agitation (CMAI), and psychotropic drug use in Dutch nursing home patients with young‐onset dementia

                                                                                 Total Psychotropic Drugs                          Antipsychotic Drugs   Anxiolytic Drugs   Antidepressant Drugs                              Hypnotics                                                                      
  ------------------------------------------------------------------------------ ------------------------------------------------- --------------------- ------------------ ------------------------------------------------- ----------- ---------- ------ ------ ------ ------ ------ ------ ------ ------ ------
  Age                                                                            1.00                                              0.95                  1.05               1.00                                              0.96        1.05       1.00   0.95   1.04   1.01   0.97   1.05   0.97   0.92   1.03
  Gender (male)                                                                  **2.14** [e](#gps5116-note-0015){ref-type="fn"}   **1.05**              **4.34**           1.61                                              0.91        2.83       0.96   0.53   1.73   1.42   0.82   2.44   0.69   0.34   1.40
  GDS 2‐5 (GDS 6‐7 reference)                                                    0.90                                              0.39                  2.12               1.15                                              0.57        2.31       0.51   0.24   1.07   1.20   0.62   2.33   0.71   0.29   1.72
  Non‐Alzheimer\'s type (Alzheimer\'s type reference)                            0.88                                              0.38                  2.03               1.63                                              0.83        3.20       0.82   0.41   1.63   0.74   0.39   1.42   0.59   0.26   1.34
  CMAI physically nonaggressive behavior[a](#gps5116-note-0011){ref-type="fn"}   1.22                                              .057                  2.60               1.25                                              0.67        2.33       1.39   0.71   2.72   1.53   0.84   2.79   1.42   0.63   3.20
  Physically aggressive behavior[b](#gps5116-note-0012){ref-type="fn"}           1.48                                              0.69                  3.17               1.86                                              0.98        3.53       1.55   0.77   3.12   0.74   0.40   1.36   1.06   0.47   2.40
  Verbally agitated behavior[c](#gps5116-note-0013){ref-type="fn"}               1.51                                              0.70                  3.24               **2.54** [e](#gps5116-note-0015){ref-type="fn"}   **1.39**    **4.65**   1.28   0.67   2.44   1.44   0.80   2.59   1.11   0.52   2.36

Abbreviation: OR, odds ratio.

Physically nonaggressive behavior (pacing, aimless wandering, hiding things, hoarding things, trying to get to a different place, handling things inappropriately, general restlessness, inappropriate dressing, or undressing).

Physically aggressive behavior (hitting, pushing, scratching, cursing or verbal aggression, grabbing, screaming, spitting, and strange noises).

Verbally agitated behavior (constant unwarranted request for attention/help, complaining, repetitive sentences or questions, and negativity).[43](#gps5116-bib-0043){ref-type="ref"}

95% confidence interval (lower boundary, upper boundary).

If value 1 is not included in the 95% confidence interval, the *p* value is significant (*p* \< .05).

Of the NPSs, as measured by the NPI‐NH, depression was associated with the use of antidepressants (or 2.30, *p* = .27); apathy was negatively associated with psychotropic drugs in general (or 0.16, *p* = .008) and with the use of hypnotics (or 0.24, *p* = .010). Nighttime behavior was positively associated with the use of hypnotics (or 8.72, *p* = .000).

In the analysis of the associations with agitation, as measured by the CMAI, verbal agitation was associated with a higher risk of antipsychotic drug use (or 2.54, *p* = .002).

4. DISCUSSION {#gps5116-sec-0018}
=============

This study is to our knowledge the first to describe the prevalence and patient‐related correlations of psychotropic drug use of institutionalized YOD patients in nursing homes. Over 80% of these YOD patients used at least one psychotropic drug, of which antipsychotics and antidepressants were each used by 50% of the patients. Almost half of the users had a combination of two or more psychotropic drugs.

Male patients had a two times higher risk of using psychotropic drugs. Dementia severity measured by GDS showed that mild to moderate dementia was associated with more use of anxiolytics than patients in a more severe stage. Non‐AD type was associated with a higher risk of using antipsychotics. The latter two findings should be interpreted with caution since these effects only reached statistical significance in the NPI model. Patients with depression had a higher risk of using antidepressants, verbal agitation resulted in a greater risk of using antipsychotics, and nighttime behavior was positively associated with the use of anxiolytics and sedatives.

Apathy showed a strongly negative correlation with use of psychotropic drugs overall and sedatives in particular.

The prevalence rates of psychotropic drug use we found in this study are slightly higher or in the same range compared with LOD patients in nursing homes.[25](#gps5116-bib-0025){ref-type="ref"}, [26](#gps5116-bib-0026){ref-type="ref"}, [44](#gps5116-bib-0044){ref-type="ref"} Several studies found that lower age was associated with higher rates of (multiple) psychotropic drug use compared with older patients.[26](#gps5116-bib-0026){ref-type="ref"}, [27](#gps5116-bib-0027){ref-type="ref"}, [29](#gps5116-bib-0029){ref-type="ref"}, [45](#gps5116-bib-0045){ref-type="ref"}, [46](#gps5116-bib-0046){ref-type="ref"} We found a lower prevalence of PRN‐prescribed antipsychotics, although we found a higher PRN prescription of anxiolytic drugs compared with studies with LOD patients.[29](#gps5116-bib-0029){ref-type="ref"}, [45](#gps5116-bib-0045){ref-type="ref"}, [47](#gps5116-bib-0047){ref-type="ref"}

Data on PDU in YOD patients are scarce. Some results are available from studies in community‐dwelling YOD patients. In one study, PDU was also high[30](#gps5116-bib-0030){ref-type="ref"} but not as high as in the institutionalized YOD population. In another part of the same study, it was demonstrated that the presence of NPS was a predictor for institutionalization[10](#gps5116-bib-0010){ref-type="ref"} and the prevalence of NPS was substantially higher in the institutionalized group compared with the community‐dwelling group. Since the presence and severity of NPS may be a predictor for PDU, this may be an explanation for the higher use of PD in institutionalized YOD patients. On the other hand, this raises the question of efficacy of psychotropic drugs for the management of NPS. Apparently, the NPSs are still present but may have been mitigated by the drugs to a more acceptable level. The difference in PDU may be due not only to differences in people with YOD or LOD but also to differences in prescribing patterns in different countries or to the difference in underlying diagnoses in the two groups; eg, AlcD and Huntington\'s disease are known to result in relatively high PDU.[48](#gps5116-bib-0048){ref-type="ref"}, [49](#gps5116-bib-0049){ref-type="ref"} Another explanation may be the higher impact of agitated or aggressive behavior on staff, thus leading to a demand for the prescription of psychotropic drugs.[50](#gps5116-bib-0050){ref-type="ref"}

We found an association between male gender and psychotropic drug use in general. In literature, we find contradicting results on the association of PDU with gender. In some LOD studies, psychotropic drugs were positively associated with male gender[44](#gps5116-bib-0044){ref-type="ref"}, [46](#gps5116-bib-0046){ref-type="ref"}; other studies found no correlation with gender[28](#gps5116-bib-0028){ref-type="ref"}, [29](#gps5116-bib-0029){ref-type="ref"} or found that females are more likely to be prescribed psychotropic drugs.[26](#gps5116-bib-0026){ref-type="ref"}, [45](#gps5116-bib-0045){ref-type="ref"}

Dementia severity in our study was not significantly associated with PDU; only the use of anxiolytics showed a significant association with dementia severity. This is in line with previous LOD studies[26](#gps5116-bib-0026){ref-type="ref"}, [29](#gps5116-bib-0029){ref-type="ref"}, [51](#gps5116-bib-0051){ref-type="ref"} finding no association with PDU in general. Assuming that NPSs are the most important indication for PDU, the variation in NPS, with some symptoms increasing and other symptoms subsiding with advancing dementia,[52](#gps5116-bib-0052){ref-type="ref"}, [53](#gps5116-bib-0053){ref-type="ref"} may explain the relatively stable use of PD during the course of the disease.

In concordance with a Norwegian study,[28](#gps5116-bib-0028){ref-type="ref"} there were significant associations between the different groups of drugs and specific NPSs in the case of depressive symptoms and the use of antidepressants, nighttime behaviors and the use of anxiolytics or hypnotics, and verbal agitation with the use of antipsychotics.

In contrast to the aforementioned study, we found that patients with apathy were much less likely to use psychotropic drugs in general or sedatives in particular. This finding is in line with the current understanding that apathy occurs frequently in dementia as a separate NPS requiring appropriate attention[54](#gps5116-bib-0054){ref-type="ref"}, [55](#gps5116-bib-0055){ref-type="ref"} and does not have to be the result of (excess) psychotropic drug use in nursing homes. Apathy in YOD has an important impact on patients and their caregivers,[10](#gps5116-bib-0010){ref-type="ref"} and to influence, this may be regarded as one of the most important challenges in informal and professional care for persons with YOD.

One of the major strengths of our study is that we had access to a relatively large group of institutionalized YOD patients, residing in comparable care settings with availability of complete medical records including all prescribed drugs.

There are also some limitations to this study. First, the drug dose was not taken into account. Therefore, it was not possible to evaluate the dosage. Due to absence of data on the actual administration of PRN prescriptions, PDU may be underestimated. Furthermore, reasons for drug prescription, the severity of the symptoms when the drugs were first administered, and the duration of usage were not available for analysis, so only assumptions can be made based on concomitant existence of NPS and the use of drugs. We used the type of dementia as a determinant of psychotropic drug use, but the type of dementia is based on the clinical diagnosis, which may not be accurate in some patients.

The selection of patients in specialized YOD care units may result in bias. In the YOD‐specialized care units, a skilled multidisciplinary staff and a comprehensive program for NPS management are key components of care. This may have resulted in a selection of patients with more challenging behavior in these care units, where patients with less NPS may be more likely to be taken care of at home or in a regular care facility nearby. On the other hand, more skilled teams and better equipped facilities may result in less psychotropic drug use, compared with care for YOD patients in less adapted facilities.

Because of the amount of variables in the analysis, there is a chance of type I error. However, for this first explorative study on NPS in institutionalized YOD patients, we chose to keep relevant variables in the model, with respect to the rule of thumb regarding the amount of events per variable. In case of total psychotropic drug use and the use of antipsychotics, the associations shown are strong and reliable. However, in the case of anxiolytics and hypnotics, groups were smaller, and therefore, the results should be interpreted with more caution.

5. CONCLUSION {#gps5116-sec-0019}
=============

In conclusion, we demonstrated that PDU in institutionalized YOD patients is very high and also, the use of multiple psychotropic drugs is widespread. A recent study showed that in only a minority of cases, the prescriptions psychotropic drugs for NPS in dementia were completely appropriate.[56](#gps5116-bib-0056){ref-type="ref"} It is likely that this is also the case in prescriptions for YOD patients. These results show the need for implementation of guidelines on psychotropic drug use and for nonpharmacological options to reduce the prevalence of NPS in specialized care units.

On the basis of the results of this first study to describe the prevalence and determinants of psychotropic drug use of patients with YOD in nursing homes, we can conclude that more research is needed on psychotropic drug use in patients with YOD, especially the changes in use over time, and evaluation of effectiveness of nonpharmacological interventions for NPS such as training of nurses, person‐centered care, and individualized structured day programs. Monitoring the effect of implementation of recent guidelines[57](#gps5116-bib-0057){ref-type="ref"} for adequate prescription of psychotropic drug use specifically in the YOD population may provide additional information on specific requirements and challenges this group brings about in nursing homes.
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